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ABSTRACT 
The secreted hexameric form of the dengue virus non-structural protein 1 (NS1) has recently 
been shown to elicit inflammatory cytokine release and disrupt endothelial cell monolayer 
integrity. This suggests that circulating NS1 contributes to the vascular leak that plays a major 
role in the pathology of dengue haemorrhagic fever and shock. Pathways activated by NS1 
are thus of great interest as potential therapeutic targets. Recent works have separately 
implicated both Toll-like receptor 4 (TLR4) and the TLR2/6 heterodimer in immune cell 
activation by NS1. Here we have used mouse gene knockout macrophages and antibodies 
blocking TLR function in human peripheral blood mononuclear cells to show that 
recombinant NS1, expressed and purified from eukaryotic cells, induces cytokine production 
via TLR4 but not TLR2/6. Furthermore, the commercial E. coli-derived recombinant NS1 
preparation used in other work to implicate TLR2/6 in the response is not correctly folded and 
appears to be contaminated by several microbial TLR ligands. Thus TLR4 remains a 
therapeutic target for dengue virus infections, with TLR4 antagonists holding promise for the 
treatment of dengue disease. 
 
 
INTRODUCTION 
The dengue virus (DENV) NS1 protein functions intracellularly to promote viral replication, 
but is also secreted from infected mammalian cells as a 300 kDa hexameric glycoprotein.1 
This hexameric species is found circulating in the blood of infected individuals and its 
presence is used for the rapid diagnosis of DENV infection.2 Recent results suggest a critical 
role for NS1 in the vascular leak that characterises severe infection.3,4 We demonstrated that 
NS1 activates both immune and endothelial cells via engagement with TLR4, leading to 
cytokine secretion and endothelial cell monolayer disruption.3 Furthermore, we found that 
TLR2 was not involved in the response to NS1. The best-studied ligand for the TLR4/MD-2 
complex is bacterial lipopolysaccharide (LPS),5,6 although a number of viral proteins 
including Ebola virus glycoprotein, respiratory syncytial virus F protein, and human 
immunodeficiency virus Tat protein, have also been shown to be TLR4 agonists.7-9 In 
contrast, Chen and colleagues10 reported that NS1 activates human and murine immune cells 
via TLR2 and TLR6, which otherwise act as a heterodimer in the recognition of diacylated 
lipoproteins from some Gram-positive bacteria and Mycoplasma.11,12 To resolve these 
apparently contradictory reports on innate immune recognition of NS1, we assessed the roles 
of TLR2, TLR4 and TLR6 in response to the different sources of NS1 used in the two 
papers.3,10 
 
RESULTS AND DISCUSSION 
Chen et al.10 used commercially available recombinant E. coli-derived NS1 (Abcam Cat. # 
64456) in experiments implicating TLR2/6 in recognition of NS1. The Abcam product is C-
terminally His-tagged NS1 from DENV-1, supplied in 1.5 M urea and recommended for use 
in ELISA and western blot applications. We first compared the oligomeric state of E. coli-
derived NS1 to DENV-2 NS1 immunoaffinity-purified from the supernatant of stably-
transfected S2 cells (“insect NS1”),3 or from the medium of DENV-2 infected Vero cells 
cultured without serum (“native NS1”). The secreted form of NS1 has a barrel-like hexameric 
structure formed by a trimer of stable NS1 dimers. The formation of this oligomeric structure 
is dependent on both glycosylation and correct disulphide bonding of the 12 cysteines in 
NS1.13-17 Immunoaffinity-purified preparations of NS1 used routinely in our laboratory are 
hexameric, based on both size exclusion chromatography and electron microscopic (EM) 
analysis (Modhiran et al.3 Figure S1). Chemical cross-linking confirms the hexameric nature 
of the particles seen on EM.15 Insect cell-expressed NS1 hexamers dissociate to dimers upon 
SDS-PAGE analysis of unboiled samples, and to monomers after boiling15, regardless of the 
presence or absence of reducing agent (Figure 1). In contrast, the commercially available E. 
coli-derived NS1 was monomeric under all conditions, with an unknown low molecular 
weight product also noted. Thus the E. coli-derived NS1 is not in its native conformation and 
is likely denatured given that it is supplied in 1.5 M urea. Such a misfolded protein may be 
suitable as an antigen substrate for western blot and qualitative ELISA analyses using 
antibodies recognising linear epitopes, but are less likely to be functional in receptor 
activation studies, that generally rely on protein structure-based interactions.  
 
Antibodies specific for human TLR2 and TLR6 were used by Chen et al. to demonstrate 
inhibition of IL-6 production by human PBMC in response to E. coli-derived NS1.10 Using 
these antibodies, we found no effect of TLR2 or TLR6 blockade on the response to insect 
NS1 (Figure 2a). As expected for PBMC from four different donors, the absolute level of 
response to stimuli was variable, but in all cases the activity of insect-derived NS1 was 
completely prevented by anti-TLR4 antibody as well as the TLR4 antagonist, Rhodobacter 
sphaeroides LPS (LPS-RS)18 (Figure 2a), in agreement with our previous work.3 Responses 
to the control TLR2/6 stimulus Pam2CSK4 and TLR4 stimulus LPS were sensitive to the 
respective anti-TLR antibodies, as expected. However, none of these TLR-inhibitory agents 
affected the response to E. coli NS1 (Figure 2a), suggesting that it may be contaminated with 
a variety of TLR ligands acting redundantly. The dominant contaminants from E. coli are 
likely to be LPS and a number of TLR2/1 agonists including triacylated lipopeptides.19,20 
Despite using the same sources of E. coli-derived NS1 and blocking antibodies we were 
unable to replicate the results of Chen et al.10 One possible explanation for their results is that 
the TLR-targeting antibodies bound to cells may lead to cell death if used in combination with 
serum that has not been adequately heat inactivated to destroy complement function, whilst 
isotype control antibodies that do not bind cells would have no effect. It is notable that in one 
experiment shown by Chen et al., anti-TLR2 and TLR6 blocking antibodies inhibited the 
PBMC response to LPS to the same extent as they inhibited the response to a TLR2/6 
ligand.10 In contrast, a supplementary figure showed LPS response unaffected by the same 
antibodies, but this data does not appear to have been generated in parallel with the relevant 
experiments. 
 
A further assessment of TLR-dependence was performed with bone marrow-derived 
macrophages (BMMs) from Tlr knockout mice. Activity of the insect-derived NS1 was lost in 
Tlr4-/- cells, but was unaffected by knockout of Tlr1 or Tlr6 (Figure 2b). Our prior work using 
Tlr2-/- BMM similarly showed no role for TLR2 in the stimulatory activity of purified insect-
derived NS1.3 Similar to results with PBMC cultures, E. coli-derived NS1 at 10 µg/ml was 
strongly active, with this activity not abolished by any individual Tlr knockout. However at 1 
µg/ml, its induction of IL-6 was TLR4-dependent. This was distinct from the human cell 
response, where TLR4 responses did not clearly dominate at this concentration of E. coli NS1 
(Figure 2a). This may reflect greater sensitivity of the human cells to possible contaminants 
within the preparation. Overall, these results cannot be reconciled with those of Chen et al.10 
who reported that the response to E. coli-derived NS1 was completely lost in Tlr6-/- mouse 
macrophages. 
  
Any study proposing a new ligand for TLR activation must exclude microbial contaminants.21 
Chen and co-workers10 used a synthetic 6X His tag peptide (Abcam Cat. # 14943) as a control 
for NS1, however this preparation is unlikely to provide an adequate experimental control for 
possible bacterial contaminants present in a recombinant protein purified from E. coli. We 
used a Limulus amoebocyte lysate (LAL) assay to estimate the LPS content in 1 µg/ml of the 
commercially sourced E. coli-derived NS1 to be 0.55 EU/ml, whilst 10 µg/ml insect-derived 
NS1 was below the limit of detection (<0.1 EU/ml). The E. coli-derived NS1 preparation was 
active in induction of IL-6 by PBMC at concentrations as low as 0.64 ng/ml NS1, which was 
approximately 1000-fold more potent than insect cell-derived NS1 (Figures 3a and 3b). The 
LPS-binding antibiotic polymyxin B had no effect on the response to insect-cell derived NS1 
(Figure 3a), showing a lack of any accessible LPS as being responsible for its activity. In 
contrast, E. coli-derived NS1 activity was reproducibly inhibited by polymyxin B, but only at 
low concentrations of NS1 (Figure 3b), suggesting the presence of a number of 
immunostimulatory agents including LPS. LPS and Pam2CSK4 treatments were used as 
positive and negative controls for TLR4 and TLR2/6 activation and polymyxin B sensitivity 
(Figures 3c and 3d). The broad dose response curve seen with E. coli-derived NS1 is also 
consistent with it containing a number of stimulatory contaminants. In contrast, purified 
insect cell-derived NS1, ultrapure LPS and Pam2CSK4 showed saturation of responses within 
1-2 log units (Figures 3a-d). 
 
The molar concentrations required for response to insect NS1 were approximately 10-fold 
higher than for LPS (Figures 3a and 3c). Whilst NS1 is a somewhat less potent agonist, 
concentrations of circulating NS1 seen in dengue virus infected patients are higher than levels 
of circulating LPS in bacterial sepsis. The median LPS reported in sepsis is 300 pg/ml (0.03 
nM assuming molecular weight of 10 kDa), ranging up to 5 ng/ml (0.5 nM).22 NS1 is detected 
in serum at ng/ml to µg/ml levels (1 µg/ml is 3.3 nM).23-25 Consequently, active 
concentrations of NS1 are within its physiological range. In addition, NS1 may be sequestered 
in vivo, for example by binding to endothelial cells,26 or masked by antibody, and its 
functional concentration may be higher than that measurable in serum. 
 
The results presented here clearly show the inadequacy of commercial bacterial-expressed 
NS1 for studies of innate immune responses, due to protein misfolding and likely 
immunostimulatory contaminants. Although Chen et al.10 used a combination of E. coli-
expressed and baculovirus-expressed NS1, key experiments defining TLR2/6 as the receptor 
used the bacterial protein; all data in the paper other than Figures 3 A-D, G and H used only 
E. coli NS1 (Justin Chu, personal communication). The only data presented with baculovirus-
expressed NS1 suggesting a role for TLR2/6 utilised TLR2/6-transfected HEK293 cells. This 
showed a detectable but low response to all ligands tested, including LPS that should not 
activate this pathway, and consequently results are not clear. Although we have found no 
TLR2/6 response to purified insect-derived NS1, this does not exclude a role for TLR2/6 
activation in other aspects of the response to DENV infection. In fact, Chen et al. 
demonstrated that relative to wild-type mice, newborn Tlr6-/- mice had improved survival 
upon infection with high doses of DENV,10 suggesting a function for TLR6 in dengue 
pathology in this model. However a link between TLR6 and NS1 cannot currently be drawn; 
the observation of toxicity of NS1 similarly injected into newborn mice10 is compromised by 
our demonstration that the NS1 used was a denatured protein likely to contain several 
inflammatory microbial contaminants. The authors also demonstrated that TLR2 and TLR6 
are induced by DENV infection.10 This shows that they are transcriptional targets of 
inflammatory signalling pathways induced by DENV infection, but provides no evidence for 
a role of TLR2/6 in recognition of the virus. 
 
Although we provide further evidence for TLR4 recognition of purified NS1, the work 
presented here alone is not sufficient to exclude LPS as the source of TLR4-stimulating 
activity in our NS1 preparation. To this end we have previously shown complete loss of 
activity following NS1 immuno-depletion, as well as the stimulatory activity of NS1 secreted 
from mammalian cells and used without purification.3 The NS1 hexamer is a barrel-like 
structure carrying a lipid cargo in its core14,15 and whether protein or lipid is required for 
TLR4 stimulation remains to be established. It is still conceivable that trace amounts of LPS 
within tissue culture reagents could be bound and concentrated on NS1 in a manner 
inaccessible to polymyxin B and the LAL assay, with NS1 becoming an efficient delivery 
agent for LPS to the TLR4 receptor complex. Importantly, any such function would be 
biologically relevant, since there are detectable amounts of LPS in circulation, particularly in 
the portal vein draining the gut.27 Indeed it is worth noting that circulating LPS levels become 
further elevated in DENV infection, possibly via gut leakiness, and may play a role in 
pathology.28 However, in support of an LPS-independent role for NS1, is its increased activity 
relative to LPS in induction of human compared with mouse cytokine mRNAs, and the 
greater effectiveness of NS1 than LPS in the disruption of endothelial monolayers.3 
Irrespective of the underlying mechanism, the TLR4 antagonist LPS-RS prevented vascular 
leak in DENV-infected mice.3 This finding emphasises the importance of TLR4 responses in 
this disease, and the potential for therapeutic reduction of pathology with TLR4 antagonists. 
 
METHODS 
Materials  
Ultrapure LPS  from  E. coli  0111:B4  strain, ultrapure LPS-RS, Pam2CSK4 and  polymyxin  
B  were  obtained  from InvivoGen (San Diego, CA, USA). The anti-TLR2 and anti-TLR6 
antibodies were purchased from InvivoGen (MAb-hTLR2 and Anti-hTLR6-IgG). The anti-
TLR4 antibody was prepared in-house by transient expression of heavy and light chains 
encoding mouse HTA125 antibody29 in CHO cells.3 Mouse IgG1 and IgG2a isotype control 
antibodies were purified from ascites fluid using a protein G column. E. coli-expressed 
DENV1 NS1 was purchased from Abcam (Melbourne, Australia. Cat. # 64456).  
 
Cell culture 
BMMs were  obtained by differentiation of mouse bone marrow progenitors of  Tlr1-/-, 
Tlr4-/-, Tlr6-/- and C57BL/6 mice in the presence of 104 U/ml CSF1 for 7 days.30 Breeding 
and use of mice was approved by the University of Queensland and James Cook University 
Animal Ethics Committees. Blood was obtained from healthy donors to the Red Cross Blood 
Service, under approval from the University of Queensland Medical Research Ethics 
Committee, and PBMCs were isolated by Ficoll gradient.31  
 
Generation and purification of DENV NS1 
The recombinant DENV2 NS1 protein was expressed in stably transfected Drosophila S2 
cells as previous described.3 Native DENV2 NS1 was prepared from medium of Vero cells 
infected by DENV2 strain ET00.300 (GenBank: AY422469.1) at multiplicity of 1 and 
maintained in serum free opti-MEM I medium (Invitrogen) for 5 days. The recombinant and 
native NS1 proteins were affinity purified from culture medium using immobilised 2A5.1 
anti-NS1 monoclonal antibody.3 The purified proteins were concentrated and the buffer 
exchanged using an Amicon 100 kDa cutoff filter (Merck Millipore, Darmstadt, Germany) 
and quantified by BCA assay (Pierce, ThermoFisher Scientific, Waltham, MA, USA). A LAL 
Chromogenic Endotoxin Quantitation Kit  (Pierce, ThermoFisher Scientific) was used to 
quantify endotoxin contamination from both insect-derived and E. coli-derived NS1. Purified 
proteins were assessed on SDS-PAGE gels stained with Coomassie blue. 
 
Detection of cytokine production by ELISA 
Mouse BMMs were seeded at 80,000 cells/well and duplicate treatment wells were incubated 
with Pam2CSK4, ultrapure LPS, E. coli-derived NS1 or insect-derived NS1 in a final volume 
of 100 µl. Mouse cell experiments were performed three times. Human PBMCs from four 
separate donors seeded at 50,000 cells/well were left untreated or pre-incubated with LPS-RS, 
anti-TLR2, anti-TLR4, anti-TLR6 antibodies or isotype control antibodies for 1 hour and 
subsequently stimulated with designated stimuli in a final volume of 100 µl. Experiments 
with human cells were performed twice with cells from two donors in each experiment. For 
both human and mouse cells, medium was harvested after 24 hours and IL-6 quantified by 
ELISA (R&D Systems, Minneapolis, MN, USA), with each sample assayed in duplicate to 
ensure reliability. No samples were excluded from analysis. 
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FIGURE LEGENDS 
 
 
 
Figure 1 E. coli-expressed NS1 does not form dimers. A 15% SDS-PAGE gel stained with 
Coomassie blue shows immunoaffinity-purified S2 cell-expressed DENV2 NS1 (insect NS1), 
E. coli-expressed DENV1 NS1 (Abcam) (E. coli NS1) and immunoaffinity-purified native 
NS1 from DENV2-infected Vero cells (native NS1), with or without sample boiling, and in 
the presence or absence of the reducing agent	 dithiothreitol (DTT). The asterisk indicates an 
unknown band in the E. coli NS1 sample.  
 
 
 
Figure 2 Purified NS1 activates mouse and human immune cell responses via TLR4 and 
not TLR2/6. (a) Purified insect cell-derived NS1 activation of PBMCs is blocked by anti-
TLR4 antibodies and TLR4 antagonist LPS-RS, but impure Abcam E. coli-derived NS1 
activity was not prevented by anti-TLR2, TLR4 or TLR6 antibodies, nor by LPS-RS. Human 
PBMCs were pre-incubated with anti-TLR2, anti-TLR4, anti-TLR6 or isotype control 
antibodies (all at 1 µg/ml), or ultrapure LPS-RS (10 µg/ml) for 1 hour and subsequently 
stimulated with TLR2/6 ligand Pam2CSK4, TLR4 ligand E. coli ultrapure LPS, E. coli-
derived NS1, or immunoaffinity-purified S2 insect cell-derived NS1. Medium was harvested 
after 24 hours and IL-6 quantified by ELISA. Data shown is mean and individual data points 
for four independent donors (n=4). (b) Purified NS1 activates mouse macrophages via TLR4. 
BMM were prepared from Tlr1-/-, Tlr4-/-, Tlr6-/- and control C57BL/6 bone marrow. BMMs 
were treated for 24 hours with Pam2CSK4, E. coli ultrapure LPS, E. coli-derived NS1, and 
insect-derived NS1. IL-6 production was measured by ELISA. Results shown are mean ± 
range of duplicate cell treatments within one experiment, and similar effects of knockouts 
were observed in two further experiments. ND = not detected. 
 
 
Figure 3 LPS-binding antibiotic polymyxin B (PxB) blocks the activity of low 
concentrations of E. coli-derived NS1, but has no effect on purified insect cell-derived 
NS1. NS1, LPS or Pam2CSK4 were pre-incubated for 30 minutes with or without polymyxin 
B in a volume of 25 µl, then added to PBMCs in 50 µl and incubated for 24 hours. The final 
concentration of polymyxin B was 2.5 µg/ml, with varying concentrations of (a) insect-
derived NS1 (2-fold dilutions from 10 µg/ml or 33.3 nM), (b) E. coli-derived NS1 (5-fold 
dilutions from 10 µg/ml or 33.3 nM) (c) E. coli ultrapure LPS (2-fold dilutions from 100 
ng/ml or 10 nM assuming average molecular weight of 10 kDa), and (d) Pam2CSK4 (2-fold 
dilutions from 100 ng/ml or 78.6 nM using molecular weight of 1271.85 Da). IL-6 production 
was quantified by ELISA. Results shown are the mean ± SEM for cells from four donors 
(n=4). 
